NEUROCRINE BIOSCIENCES INC
For the period ended Dec 31, 2025. Filed Feb 11, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 11, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 2. Properties
The following table presents information on our leased facilities.
| Location · Use · Square Feet · Expiration Date | ||||
|---|---|---|---|---|
| San Diego, California | Corporate Headquarters, Office and Laboratory | 535,000 | October 31, 2036 | |
| San Diego, California | Office and Laboratory | 229,000 | (1) | July 31, 2031 |
| San Diego, California | Office | 45,000 | (2) | April 30, 2029 |
| Washington, DC | Office | 5,300 | August 31, 2027 | |
(1) This property is associated with our former corporate headquarters. Approximately 73,000 square feet are subleased by multiple third parties for general office space through the remaining term of the lease.
(2) This property is associated with our former corporate headquarters. We are actively marketing this property for sublease. Approximately 22,500 square feet are subleased by a third party for general office space through the remaining term of the lease with approximately 22,500 square feet of available space remaining.
We believe that our existing facilities are adequate to meet our current needs, and that suitable additional alternative facilities will be available in the future on commercially reasonable terms.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.